{"entity":{"type":"insider","cik":"0001801061","url":"/insider/0001801061","json_url":"/insider/0001801061.json","name":"Watanabe Todd","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":82,"n_filings":60,"first":"2020-10-01","last":"2026-08-05","span_basis":"filed_date"},"name_variants":[{"name":"Watanabe Todd","source":"filing","n_filings":10,"first_seen":"2025-08-05","last_seen":"2026-08-05"},{"name":"Watanabe Todd Franklin","source":"filing","n_filings":50,"first_seen":"2020-10-01","last_seen":"2025-05-05"}],"transactions":[{"id":5814797,"accession":"0001628280-26-053753","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001628280-26-053753","line_url":"/filing/0001628280-26-053753#line-1","is_derivative":false,"issuer_cik":"0001787306","issuer_name":"Arcutis Biotherapeutics, Inc.","issuer_ticker":"ARQT","issuer_name_source":null,"issuer_url":"/issuer/0001787306","owner_cik":"0001801061","owner_name":"Watanabe Todd","owner_display_name":"Watanabe Todd","owner_url":"/insider/0001801061","role":"Director, Officer","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"See Remarks","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":4375.0,"shares_display":"4,375","price_per_share":26.1168,"price_display":"26.12","price_state":"stated","total_value":114261.0,"total_display":"114,261.00","total_whole":"114,261","shares_owned_after":717203.0,"shares_owned_after_display":"717,203","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-08-03","filed_date":"2026-08-05","scope":"insider"},{"id":5806036,"accession":"0001801061-26-000003","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001801061-26-000003","line_url":"/filing/0001801061-26-000003#line-1","is_derivative":false,"issuer_cik":"0001787306","issuer_name":"Arcutis Biotherapeutics, Inc.","issuer_ticker":"ARQT","issuer_name_source":null,"issuer_url":"/issuer/0001787306","owner_cik":"0001801061","owner_name":"Watanabe Todd","owner_display_name":"Watanabe Todd","owner_url":"/insider/0001801061","role":"Director, Officer","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"See Remarks","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3172.0,"shares_display":"3,172","price_per_share":23.6106,"price_display":"23.61","price_state":"stated","total_value":74892.8232,"total_display":"74,892.82","total_whole":"74,893","shares_owned_after":720755.0,"shares_owned_after_display":"720,755","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-05-04","filed_date":"2026-05-06","scope":"insider"},{"id":5963122,"accession":"0001628280-26-014327","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001628280-26-014327","line_url":"/filing/0001628280-26-014327","is_derivative":false,"issuer_cik":"0001787306","issuer_name":"Arcutis Biotherapeutics, Inc.","issuer_ticker":"ARQT","issuer_name_source":null,"issuer_url":"/issuer/0001787306","owner_cik":"0001801061","owner_name":"Watanabe Todd","owner_display_name":"Watanabe Todd","owner_url":"/insider/0001801061","role":"Director, Officer","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"See Remarks","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":37349.0,"shares_display":"37,349","price_per_share":25.182140721304453,"price_display":"25.18","price_state":"stated","total_value":940527.7738,"total_display":"940,527.77","total_whole":"940,528","shares_owned_after":787025.0,"shares_owned_after_display":"787,025","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-03-02","filed_date":"2026-03-03","scope":"insider","n_lines":2},{"id":5835365,"accession":"0001628280-26-005570","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001628280-26-005570","line_url":"/filing/0001628280-26-005570#line-1","is_derivative":false,"issuer_cik":"0001787306","issuer_name":"Arcutis Biotherapeutics, Inc.","issuer_ticker":"ARQT","issuer_name_source":null,"issuer_url":"/issuer/0001787306","owner_cik":"0001801061","owner_name":"Watanabe Todd","owner_display_name":"Watanabe Todd","owner_url":"/insider/0001801061","role":"Director, Officer","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"See Remarks","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":19833.0,"shares_display":"19,833","price_per_share":25.4984,"price_display":"25.50","price_state":"stated","total_value":505709.7672,"total_display":"505,709.77","total_whole":"505,710","shares_owned_after":721306.0,"shares_owned_after_display":"721,306","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-02-02","filed_date":"2026-02-04","scope":"insider"},{"id":4395973,"accession":"0001801061-25-000012","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001801061-25-000012","line_url":"/filing/0001801061-25-000012#line-2","is_derivative":false,"issuer_cik":"0001787306","issuer_name":"Arcutis Biotherapeutics, Inc.","issuer_ticker":"ARQT","issuer_name_source":null,"issuer_url":"/issuer/0001787306","owner_cik":"0001801061","owner_name":"Watanabe Todd","owner_display_name":"Watanabe Todd","owner_url":"/insider/0001801061","role":"Director, Officer","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"See Remarks","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":48945.0,"shares_display":"48,945","price_per_share":30.3556,"price_display":"30.36","price_state":"stated","total_value":1485754.842,"total_display":"1,485,754.84","total_whole":"1,485,755","shares_owned_after":740537.0,"shares_owned_after_display":"740,537","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-11-24","filed_date":"2025-11-24","scope":"insider"},{"id":4395969,"accession":"0001801061-25-000012","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001801061-25-000012","line_url":"/filing/0001801061-25-000012#line-1","is_derivative":false,"issuer_cik":"0001787306","issuer_name":"Arcutis Biotherapeutics, Inc.","issuer_ticker":"ARQT","issuer_name_source":null,"issuer_url":"/issuer/0001787306","owner_cik":"0001801061","owner_name":"Watanabe Todd","owner_display_name":"Watanabe Todd","owner_url":"/insider/0001801061","role":"Director, Officer","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"See Remarks","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1055.0,"shares_display":"1,055","price_per_share":30.0,"price_display":"30.00","price_state":"stated","total_value":31650.0,"total_display":"31,650.00","total_whole":"31,650","shares_owned_after":793838.0,"shares_owned_after_display":"793,838","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-11-21","filed_date":"2025-11-24","scope":"insider"},{"id":4322620,"accession":"0001801061-25-000010","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001801061-25-000010","line_url":"/filing/0001801061-25-000010","is_derivative":false,"issuer_cik":"0001787306","issuer_name":"Arcutis Biotherapeutics, Inc.","issuer_ticker":"ARQT","issuer_name_source":null,"issuer_url":"/issuer/0001787306","owner_cik":"0001801061","owner_name":"Watanabe Todd","owner_display_name":"Watanabe Todd","owner_url":"/insider/0001801061","role":"Director, Officer","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"See Remarks","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":11547.0,"shares_display":"11,547","price_per_share":24.716304624577813,"price_display":"24.72","price_state":"stated","total_value":285399.1695,"total_display":"285,399.17","total_whole":"285,399","shares_owned_after":794962.0,"shares_owned_after_display":"794,962","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-11-03","filed_date":"2025-11-05","scope":"insider","n_lines":2},{"id":4252721,"accession":"0001801061-25-000008","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001801061-25-000008","line_url":"/filing/0001801061-25-000008#line-1","is_derivative":false,"issuer_cik":"0001787306","issuer_name":"Arcutis Biotherapeutics, Inc.","issuer_ticker":"ARQT","issuer_name_source":null,"issuer_url":"/issuer/0001787306","owner_cik":"0001801061","owner_name":"Watanabe Todd","owner_display_name":"Watanabe Todd","owner_url":"/insider/0001801061","role":"Director, Officer","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"See Remarks","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":40000.0,"shares_display":"40,000","price_per_share":25.0258,"price_display":"25.03","price_state":"stated","total_value":1001032.0,"total_display":"1,001,032.00","total_whole":"1,001,032","shares_owned_after":806440.0,"shares_owned_after_display":"806,440","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-10-28","filed_date":"2025-10-30","scope":"insider"},{"id":4252718,"accession":"0001801061-25-000006","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001801061-25-000006","line_url":"/filing/0001801061-25-000006#line-3","is_derivative":false,"issuer_cik":"0001787306","issuer_name":"Arcutis Biotherapeutics, Inc.","issuer_ticker":"ARQT","issuer_name_source":null,"issuer_url":"/issuer/0001787306","owner_cik":"0001801061","owner_name":"Watanabe Todd","owner_display_name":"Watanabe Todd","owner_url":"/insider/0001801061","role":"Director, Officer","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"See Remarks","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":20739.0,"shares_display":"20,739","price_per_share":20.0383,"price_display":"20.04","price_state":"stated","total_value":415574.3037,"total_display":"415,574.30","total_whole":"415,574","shares_owned_after":846440.0,"shares_owned_after_display":"846,440","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-10-02","filed_date":"2025-10-03","scope":"insider"},{"id":4252714,"accession":"0001801061-25-000006","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001801061-25-000006","line_url":"/filing/0001801061-25-000006","is_derivative":false,"issuer_cik":"0001787306","issuer_name":"Arcutis Biotherapeutics, Inc.","issuer_ticker":"ARQT","issuer_name_source":null,"issuer_url":"/issuer/0001787306","owner_cik":"0001801061","owner_name":"Watanabe Todd","owner_display_name":"Watanabe Todd","owner_url":"/insider/0001801061","role":"Director, Officer","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"See Remarks","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":24261.0,"shares_display":"24,261","price_per_share":19.334503128477802,"price_display":"19.33","price_state":"stated","total_value":469074.3804,"total_display":"469,074.38","total_whole":"469,074","shares_owned_after":876440.0,"shares_owned_after_display":"876,440","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-10-01","filed_date":"2025-10-03","scope":"insider","n_lines":2},{"id":4322471,"accession":"0001787306-25-000136","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001787306-25-000136","line_url":"/filing/0001787306-25-000136#line-2","is_derivative":false,"issuer_cik":"0001787306","issuer_name":"Arcutis Biotherapeutics, Inc.","issuer_ticker":"ARQT","issuer_name_source":null,"issuer_url":"/issuer/0001787306","owner_cik":"0001801061","owner_name":"Watanabe Todd","owner_display_name":"Watanabe Todd","owner_url":"/insider/0001801061","role":"Director, Officer","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"See Remarks","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":504.0,"shares_display":"504","price_per_share":17.5179,"price_display":"17.52","price_state":"stated","total_value":8829.0216,"total_display":"8,829.02","total_whole":"8,829","shares_owned_after":891440.0,"shares_owned_after_display":"891,440","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-09-09","filed_date":"2025-09-10","scope":"insider"},{"id":4322466,"accession":"0001787306-25-000136","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001787306-25-000136","line_url":"/filing/0001787306-25-000136#line-1","is_derivative":false,"issuer_cik":"0001787306","issuer_name":"Arcutis Biotherapeutics, Inc.","issuer_ticker":"ARQT","issuer_name_source":null,"issuer_url":"/issuer/0001787306","owner_cik":"0001801061","owner_name":"Watanabe Todd","owner_display_name":"Watanabe Todd","owner_url":"/insider/0001801061","role":"Director, Officer","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"See Remarks","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":9625.0,"shares_display":"9,625","price_per_share":17.5376,"price_display":"17.54","price_state":"stated","total_value":168799.4,"total_display":"168,799.40","total_whole":"168,799","shares_owned_after":891944.0,"shares_owned_after_display":"891,944","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-09-08","filed_date":"2025-09-10","scope":"insider"},{"id":4778000,"accession":"0001787306-25-000119","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001787306-25-000119","line_url":"/filing/0001787306-25-000119#line-1","is_derivative":false,"issuer_cik":"0001787306","issuer_name":"Arcutis Biotherapeutics, Inc.","issuer_ticker":"ARQT","issuer_name_source":null,"issuer_url":"/issuer/0001787306","owner_cik":"0001801061","owner_name":"Watanabe Todd","owner_display_name":"Watanabe Todd","owner_url":"/insider/0001801061","role":"Director, Officer","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"See Remarks","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":11547.0,"shares_display":"11,547","price_per_share":14.3266,"price_display":"14.33","price_state":"stated","total_value":165429.2502,"total_display":"165,429.25","total_whole":"165,429","shares_owned_after":901569.0,"shares_owned_after_display":"901,569","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-08-04","filed_date":"2025-08-05","scope":"insider"},{"id":4560744,"accession":"0001787306-25-000085","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001787306-25-000085","line_url":"/filing/0001787306-25-000085#line-1","is_derivative":false,"issuer_cik":"0001787306","issuer_name":"Arcutis Biotherapeutics, Inc.","issuer_ticker":"ARQT","issuer_name_source":null,"issuer_url":"/issuer/0001787306","owner_cik":"0001801061","owner_name":"Watanabe Todd Franklin","owner_display_name":"Watanabe Todd Franklin","owner_url":"/insider/0001801061","role":"Director, Officer","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"See Remarks","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":11448.0,"shares_display":"11,448","price_per_share":15.1919,"price_display":"15.19","price_state":"stated","total_value":173916.8712,"total_display":"173,916.87","total_whole":"173,917","shares_owned_after":913795.0,"shares_owned_after_display":"913,795","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-05-02","filed_date":"2025-05-05","scope":"insider"},{"id":5007234,"accession":"0001787306-25-000050","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001787306-25-000050","line_url":"/filing/0001787306-25-000050#line-2","is_derivative":false,"issuer_cik":"0001787306","issuer_name":"Arcutis Biotherapeutics, Inc.","issuer_ticker":"ARQT","issuer_name_source":null,"issuer_url":"/issuer/0001787306","owner_cik":"0001801061","owner_name":"Watanabe Todd Franklin","owner_display_name":"Watanabe Todd Franklin","owner_url":"/insider/0001801061","role":"Director, Officer","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"See Remarks","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2171.0,"shares_display":"2,171","price_per_share":17.564,"price_display":"17.56","price_state":"stated","total_value":38131.444,"total_display":"38,131.44","total_whole":"38,131","shares_owned_after":925243.0,"shares_owned_after_display":"925,243","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-03-25","filed_date":"2025-03-26","scope":"insider"},{"id":5007228,"accession":"0001787306-25-000050","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001787306-25-000050","line_url":"/filing/0001787306-25-000050#line-1","is_derivative":false,"issuer_cik":"0001787306","issuer_name":"Arcutis Biotherapeutics, Inc.","issuer_ticker":"ARQT","issuer_name_source":null,"issuer_url":"/issuer/0001787306","owner_cik":"0001801061","owner_name":"Watanabe Todd Franklin","owner_display_name":"Watanabe Todd Franklin","owner_url":"/insider/0001801061","role":"Director, Officer","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"See Remarks","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1500.0,"shares_display":"1,500","price_per_share":17.5213,"price_display":"17.52","price_state":"stated","total_value":26281.95,"total_display":"26,281.95","total_whole":"26,282","shares_owned_after":927414.0,"shares_owned_after_display":"927,414","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-03-24","filed_date":"2025-03-26","scope":"insider"},{"id":5133473,"accession":"0001787306-25-000048","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001787306-25-000048","line_url":"/filing/0001787306-25-000048#line-1","is_derivative":false,"issuer_cik":"0001787306","issuer_name":"Arcutis Biotherapeutics, Inc.","issuer_ticker":"ARQT","issuer_name_source":null,"issuer_url":"/issuer/0001787306","owner_cik":"0001801061","owner_name":"Watanabe Todd Franklin","owner_display_name":"Watanabe Todd Franklin","owner_url":"/insider/0001801061","role":"Director, Officer","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"See Remarks","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1200.0,"shares_display":"1,200","price_per_share":17.6142,"price_display":"17.61","price_state":"stated","total_value":21137.04,"total_display":"21,137.04","total_whole":"21,137","shares_owned_after":928914.0,"shares_owned_after_display":"928,914","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-03-17","filed_date":"2025-03-20","scope":"insider"},{"id":5060547,"accession":"0001787306-25-000042","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001787306-25-000042","line_url":"/filing/0001787306-25-000042#line-3","is_derivative":false,"issuer_cik":"0001787306","issuer_name":"Arcutis Biotherapeutics, Inc.","issuer_ticker":"ARQT","issuer_name_source":null,"issuer_url":"/issuer/0001787306","owner_cik":"0001801061","owner_name":"Watanabe Todd Franklin","owner_display_name":"Watanabe Todd Franklin","owner_url":"/insider/0001801061","role":"Director, Officer","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"See Remarks","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":4135.0,"shares_display":"4,135","price_per_share":13.2841,"price_display":"13.28","price_state":"stated","total_value":54929.7535,"total_display":"54,929.75","total_whole":"54,930","shares_owned_after":930114.0,"shares_owned_after_display":"930,114","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-03-04","filed_date":"2025-03-04","scope":"insider"},{"id":5060538,"accession":"0001787306-25-000042","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001787306-25-000042","line_url":"/filing/0001787306-25-000042#line-2","is_derivative":false,"issuer_cik":"0001787306","issuer_name":"Arcutis Biotherapeutics, Inc.","issuer_ticker":"ARQT","issuer_name_source":null,"issuer_url":"/issuer/0001787306","owner_cik":"0001801061","owner_name":"Watanabe Todd Franklin","owner_display_name":"Watanabe Todd Franklin","owner_url":"/insider/0001801061","role":"Director, Officer","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"See Remarks","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":20880.0,"shares_display":"20,880","price_per_share":13.0311,"price_display":"13.03","price_state":"stated","total_value":272089.368,"total_display":"272,089.37","total_whole":"272,089","shares_owned_after":934249.0,"shares_owned_after_display":"934,249","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-03-03","filed_date":"2025-03-04","scope":"insider"},{"id":4213340,"accession":"0001787306-25-000016","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001787306-25-000016","line_url":"/filing/0001787306-25-000016#line-1","is_derivative":false,"issuer_cik":"0001787306","issuer_name":"Arcutis Biotherapeutics, Inc.","issuer_ticker":"ARQT","issuer_name_source":null,"issuer_url":"/issuer/0001787306","owner_cik":"0001801061","owner_name":"Watanabe Todd Franklin","owner_display_name":"Watanabe Todd Franklin","owner_url":"/insider/0001801061","role":"Director, Officer","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"See Remarks","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":19301.0,"shares_display":"19,301","price_per_share":12.7,"price_display":"12.70","price_state":"stated","total_value":245122.7,"total_display":"245,122.70","total_whole":"245,123","shares_owned_after":804129.0,"shares_owned_after_display":"804,129","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-02-03","filed_date":"2025-02-04","scope":"insider"},{"id":2874078,"accession":"0001787306-24-000172","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001787306-24-000172","line_url":"/filing/0001787306-24-000172#line-1","is_derivative":false,"issuer_cik":"0001787306","issuer_name":"Arcutis Biotherapeutics, Inc.","issuer_ticker":"ARQT","issuer_name_source":null,"issuer_url":"/issuer/0001787306","owner_cik":"0001801061","owner_name":"Watanabe Todd Franklin","owner_display_name":"Watanabe Todd Franklin","owner_url":"/insider/0001801061","role":"Director, Officer","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"See Remarks","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":15000.0,"shares_display":"15,000","price_per_share":15.1711,"price_display":"15.17","price_state":"stated","total_value":227566.5,"total_display":"227,566.50","total_whole":"227,567","shares_owned_after":823430.0,"shares_owned_after_display":"823,430","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-12-20","filed_date":"2024-12-23","scope":"insider"},{"id":2524011,"accession":"0001787306-24-000166","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001787306-24-000166","line_url":"/filing/0001787306-24-000166#line-2","is_derivative":false,"issuer_cik":"0001787306","issuer_name":"Arcutis Biotherapeutics, Inc.","issuer_ticker":"ARQT","issuer_name_source":null,"issuer_url":"/issuer/0001787306","owner_cik":"0001801061","owner_name":"Watanabe Todd Franklin","owner_display_name":"Watanabe Todd Franklin","owner_url":"/insider/0001801061","role":"Director, Officer","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"See Remarks","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":2038.0,"shares_display":"2,038","price_per_share":7.106,"price_display":"7.11","price_state":"stated","total_value":14482.028,"total_display":"14,482.03","total_whole":"14,482","shares_owned_after":838430.0,"shares_owned_after_display":"838,430","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-11-30","filed_date":"2024-12-03","scope":"insider"},{"id":2367089,"accession":"0001787306-24-000144","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001787306-24-000144","line_url":"/filing/0001787306-24-000144#line-1","is_derivative":false,"issuer_cik":"0001787306","issuer_name":"Arcutis Biotherapeutics, Inc.","issuer_ticker":"ARQT","issuer_name_source":null,"issuer_url":"/issuer/0001787306","owner_cik":"0001801061","owner_name":"Watanabe Todd Franklin","owner_display_name":"Watanabe Todd Franklin","owner_url":"/insider/0001801061","role":"Director, Officer","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"See Remarks","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":13871.0,"shares_display":"13,871","price_per_share":8.6842,"price_display":"8.68","price_state":"stated","total_value":120458.5382,"total_display":"120,458.54","total_whole":"120,459","shares_owned_after":832392.0,"shares_owned_after_display":"832,392","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-11-04","filed_date":"2024-11-05","scope":"insider"},{"id":2071970,"accession":"0001787306-24-000116","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001787306-24-000116","line_url":"/filing/0001787306-24-000116#line-1","is_derivative":false,"issuer_cik":"0001787306","issuer_name":"Arcutis Biotherapeutics, Inc.","issuer_ticker":"ARQT","issuer_name_source":null,"issuer_url":"/issuer/0001787306","owner_cik":"0001801061","owner_name":"Watanabe Todd Franklin","owner_display_name":"Watanabe Todd Franklin","owner_url":"/insider/0001801061","role":"Director, Officer","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"See Remarks","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":14487.0,"shares_display":"14,487","price_per_share":9.0183,"price_display":"9.02","price_state":"stated","total_value":130648.1121,"total_display":"130,648.11","total_whole":"130,648","shares_owned_after":846263.0,"shares_owned_after_display":"846,263","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-08-02","filed_date":"2024-08-05","scope":"insider"},{"id":2524009,"accession":"0001787306-24-000166","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001787306-24-000166","line_url":"/filing/0001787306-24-000166#line-1","is_derivative":false,"issuer_cik":"0001787306","issuer_name":"Arcutis Biotherapeutics, Inc.","issuer_ticker":"ARQT","issuer_name_source":null,"issuer_url":"/issuer/0001787306","owner_cik":"0001801061","owner_name":"Watanabe Todd Franklin","owner_display_name":"Watanabe Todd Franklin","owner_url":"/insider/0001801061","role":"Director, Officer","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"See Remarks","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":4000.0,"shares_display":"4,000","price_per_share":1.692,"price_display":"1.69","price_state":"stated","total_value":6768.0,"total_display":"6,768.00","total_whole":"6,768","shares_owned_after":836392.0,"shares_owned_after_display":"836,392","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-05-31","filed_date":"2024-12-03","scope":"insider"},{"id":2295232,"accession":"0001787306-24-000070","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001787306-24-000070","line_url":"/filing/0001787306-24-000070#line-1","is_derivative":false,"issuer_cik":"0001787306","issuer_name":"Arcutis Biotherapeutics, Inc.","issuer_ticker":"ARQT","issuer_name_source":null,"issuer_url":"/issuer/0001787306","owner_cik":"0001801061","owner_name":"Watanabe Todd Franklin","owner_display_name":"Watanabe Todd Franklin","owner_url":"/insider/0001801061","role":"Director, Officer","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"See Remarks","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":13783.0,"shares_display":"13,783","price_per_share":8.7378,"price_display":"8.74","price_state":"stated","total_value":120433.0974,"total_display":"120,433.10","total_whole":"120,433","shares_owned_after":860750.0,"shares_owned_after_display":"860,750","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-05-02","filed_date":"2024-05-03","scope":"insider"},{"id":3190094,"accession":"0001787306-24-000038","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001787306-24-000038","line_url":"/filing/0001787306-24-000038#line-1","is_derivative":false,"issuer_cik":"0001787306","issuer_name":"Arcutis Biotherapeutics, Inc.","issuer_ticker":"ARQT","issuer_name_source":null,"issuer_url":"/issuer/0001787306","owner_cik":"0001801061","owner_name":"Watanabe Todd Franklin","owner_display_name":"Watanabe Todd Franklin","owner_url":"/insider/0001801061","role":"Director, Officer","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"See Remarks","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":14903.0,"shares_display":"14,903","price_per_share":11.1212,"price_display":"11.12","price_state":"stated","total_value":165739.2436,"total_display":"165,739.24","total_whole":"165,739","shares_owned_after":874533.0,"shares_owned_after_display":"874,533","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-03-04","filed_date":"2024-03-06","scope":"insider"},{"id":2166044,"accession":"0001787306-24-000034","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001787306-24-000034","line_url":"/filing/0001787306-24-000034#line-1","is_derivative":false,"issuer_cik":"0001787306","issuer_name":"Arcutis Biotherapeutics, Inc.","issuer_ticker":"ARQT","issuer_name_source":null,"issuer_url":"/issuer/0001787306","owner_cik":"0001801061","owner_name":"Watanabe Todd Franklin","owner_display_name":"Watanabe Todd Franklin","owner_url":"/insider/0001801061","role":"Director, Officer","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"See Remarks","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2465.0,"shares_display":"2,465","price_per_share":10.6,"price_display":"10.60","price_state":"stated","total_value":26129.0,"total_display":"26,129.00","total_whole":"26,129","shares_owned_after":889436.0,"shares_owned_after_display":"889,436","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-02-28","filed_date":"2024-03-01","scope":"insider"},{"id":8453979,"accession":"0001787306-23-000129","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001787306-23-000129","line_url":"/filing/0001787306-23-000129#line-1","is_derivative":false,"issuer_cik":"0001787306","issuer_name":"Arcutis Biotherapeutics, Inc.","issuer_ticker":"ARQT","issuer_name_source":null,"issuer_url":"/issuer/0001787306","owner_cik":"0001801061","owner_name":"Watanabe Todd Franklin","owner_display_name":"Watanabe Todd Franklin","owner_url":"/insider/0001801061","role":"Director, Officer","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"See Remarks","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":1463.0,"shares_display":"1,463","price_per_share":6.38,"price_display":"6.38","price_state":"stated","total_value":9333.94,"total_display":"9,333.94","total_whole":"9,334","shares_owned_after":515145.0,"shares_owned_after_display":"515,145","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-05-31","filed_date":"2023-12-01","scope":"insider"},{"id":8714871,"accession":"0001567619-23-004672","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001567619-23-004672","line_url":"/filing/0001567619-23-004672#line-1","is_derivative":false,"issuer_cik":"0001787306","issuer_name":"Arcutis Biotherapeutics, Inc.","issuer_ticker":"ARQT","issuer_name_source":null,"issuer_url":"/issuer/0001787306","owner_cik":"0001801061","owner_name":"Watanabe Todd Franklin","owner_display_name":"Watanabe Todd Franklin","owner_url":"/insider/0001801061","role":"Director, Officer","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"See Remarks","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2435.0,"shares_display":"2,435","price_per_share":15.2638,"price_display":"15.26","price_state":"stated","total_value":37167.353,"total_display":"37,167.35","total_whole":"37,167","shares_owned_after":366657.0,"shares_owned_after_display":"366,657","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-03-06","filed_date":"2023-03-08","scope":"insider"},{"id":8338108,"accession":"0001567619-23-004272","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001567619-23-004272","line_url":"/filing/0001567619-23-004272","is_derivative":false,"issuer_cik":"0001787306","issuer_name":"Arcutis Biotherapeutics, Inc.","issuer_ticker":"ARQT","issuer_name_source":null,"issuer_url":"/issuer/0001787306","owner_cik":"0001801061","owner_name":"Watanabe Todd Franklin","owner_display_name":"Watanabe Todd Franklin","owner_url":"/insider/0001801061","role":"Director, Officer","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"See Remarks","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":5472.0,"shares_display":"5,472","price_per_share":15.827049451754386,"price_display":"15.83","price_state":"stated","total_value":86605.6146,"total_display":"86,605.61","total_whole":"86,606","shares_owned_after":369161.0,"shares_owned_after_display":"369,161","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-03-02","filed_date":"2023-03-02","scope":"insider","n_lines":2},{"id":8338092,"accession":"0001567619-23-004272","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001567619-23-004272","line_url":"/filing/0001567619-23-004272#line-1","is_derivative":false,"issuer_cik":"0001787306","issuer_name":"Arcutis Biotherapeutics, Inc.","issuer_ticker":"ARQT","issuer_name_source":null,"issuer_url":"/issuer/0001787306","owner_cik":"0001801061","owner_name":"Watanabe Todd Franklin","owner_display_name":"Watanabe Todd Franklin","owner_url":"/insider/0001801061","role":"Director, Officer","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"See Remarks","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2343.0,"shares_display":"2,343","price_per_share":16.1663,"price_display":"16.17","price_state":"stated","total_value":37877.6409,"total_display":"37,877.64","total_whole":"37,878","shares_owned_after":374564.0,"shares_owned_after_display":"374,564","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-02-28","filed_date":"2023-03-02","scope":"insider"},{"id":8565850,"accession":"0001787306-23-000008","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001787306-23-000008","line_url":"/filing/0001787306-23-000008","is_derivative":false,"issuer_cik":"0001787306","issuer_name":"Arcutis Biotherapeutics, Inc.","issuer_ticker":"ARQT","issuer_name_source":null,"issuer_url":"/issuer/0001787306","owner_cik":"0001801061","owner_name":"Watanabe Todd Franklin","owner_display_name":"Watanabe Todd Franklin","owner_url":"/insider/0001801061","role":"Director, Officer","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"See Remarks","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":517.0,"shares_display":"517","price_per_share":17.02193423597679,"price_display":"17.02","price_state":"stated","total_value":8800.34,"total_display":"8,800.34","total_whole":"8,800","shares_owned_after":377007.0,"shares_owned_after_display":"377,007","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-02-14","filed_date":"2023-02-15","scope":"insider","n_lines":2},{"id":8565843,"accession":"0001787306-23-000008","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001787306-23-000008","line_url":"/filing/0001787306-23-000008","is_derivative":false,"issuer_cik":"0001787306","issuer_name":"Arcutis Biotherapeutics, Inc.","issuer_ticker":"ARQT","issuer_name_source":null,"issuer_url":"/issuer/0001787306","owner_cik":"0001801061","owner_name":"Watanabe Todd Franklin","owner_display_name":"Watanabe Todd Franklin","owner_url":"/insider/0001801061","role":"Director, Officer","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"See Remarks","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":483.0,"shares_display":"483","price_per_share":17.000869565217393,"price_display":"17.00","price_state":"stated","total_value":8211.42,"total_display":"8,211.42","total_whole":"8,211","shares_owned_after":377466.0,"shares_owned_after_display":"377,466","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-02-13","filed_date":"2023-02-15","scope":"insider","n_lines":2},{"id":7826887,"accession":"0001787306-23-000006","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001787306-23-000006","line_url":"/filing/0001787306-23-000006","is_derivative":false,"issuer_cik":"0001787306","issuer_name":"Arcutis Biotherapeutics, Inc.","issuer_ticker":"ARQT","issuer_name_source":null,"issuer_url":"/issuer/0001787306","owner_cik":"0001801061","owner_name":"Watanabe Todd Franklin","owner_display_name":"Watanabe Todd Franklin","owner_url":"/insider/0001801061","role":"Director, Officer","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"See Remarks","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1000.0,"shares_display":"1,000","price_per_share":17.0027192,"price_display":"17.00","price_state":"stated","total_value":17002.7192,"total_display":"17,002.72","total_whole":"17,003","shares_owned_after":378289.0,"shares_owned_after_display":"378,289","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-02-01","filed_date":"2023-02-03","scope":"insider","n_lines":2},{"id":6989661,"accession":"0001787306-22-000079","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001787306-22-000079","line_url":"/filing/0001787306-22-000079#line-1","is_derivative":false,"issuer_cik":"0001787306","issuer_name":"Arcutis Biotherapeutics, Inc.","issuer_ticker":"ARQT","issuer_name_source":null,"issuer_url":"/issuer/0001787306","owner_cik":"0001801061","owner_name":"Watanabe Todd Franklin","owner_display_name":"Watanabe Todd Franklin","owner_url":"/insider/0001801061","role":"Director, Officer","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"See Remarks","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1000.0,"shares_display":"1,000","price_per_share":17.06,"price_display":"17.06","price_state":"stated","total_value":17060.0,"total_display":"17,060.00","total_whole":"17,060","shares_owned_after":378907.0,"shares_owned_after_display":"378,907","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-12-07","filed_date":"2022-12-09","scope":"insider"},{"id":6292160,"accession":"0001787306-22-000073","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001787306-22-000073","line_url":"/filing/0001787306-22-000073#line-1","is_derivative":false,"issuer_cik":"0001787306","issuer_name":"Arcutis Biotherapeutics, Inc.","issuer_ticker":"ARQT","issuer_name_source":null,"issuer_url":"/issuer/0001787306","owner_cik":"0001801061","owner_name":"Watanabe Todd Franklin","owner_display_name":"Watanabe Todd Franklin","owner_url":"/insider/0001801061","role":"Director, Officer","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"See Remarks","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1000.0,"shares_display":"1,000","price_per_share":18.004,"price_display":"18.00","price_state":"stated","total_value":18004.0,"total_display":"18,004.00","total_whole":"18,004","shares_owned_after":379907.0,"shares_owned_after_display":"379,907","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-11-07","filed_date":"2022-11-09","scope":"insider"},{"id":6356101,"accession":"0001567619-22-018418","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001567619-22-018418","line_url":"/filing/0001567619-22-018418#line-1","is_derivative":false,"issuer_cik":"0001787306","issuer_name":"Arcutis Biotherapeutics, Inc.","issuer_ticker":"ARQT","issuer_name_source":null,"issuer_url":"/issuer/0001787306","owner_cik":"0001801061","owner_name":"Watanabe Todd Franklin","owner_display_name":"Watanabe Todd Franklin","owner_url":"/insider/0001801061","role":"Director, Officer (President and CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President and CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1000.0,"shares_display":"1,000","price_per_share":19.51,"price_display":"19.51","price_state":"stated","total_value":19510.0,"total_display":"19,510.00","total_whole":"19,510","shares_owned_after":380907.0,"shares_owned_after_display":"380,907","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-10-07","filed_date":"2022-10-11","scope":"insider"},{"id":6434418,"accession":"0001567619-22-017237","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001567619-22-017237","line_url":"/filing/0001567619-22-017237#line-2","is_derivative":false,"issuer_cik":"0001787306","issuer_name":"Arcutis Biotherapeutics, Inc.","issuer_ticker":"ARQT","issuer_name_source":null,"issuer_url":"/issuer/0001787306","owner_cik":"0001801061","owner_name":"Watanabe Todd Franklin","owner_display_name":"Watanabe Todd Franklin","owner_url":"/insider/0001801061","role":"Director, Officer (President and CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President and CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1000.0,"shares_display":"1,000","price_per_share":21.51,"price_display":"21.51","price_state":"stated","total_value":21510.0,"total_display":"21,510.00","total_whole":"21,510","shares_owned_after":381907.0,"shares_owned_after_display":"381,907","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-09-07","filed_date":"2022-09-09","scope":"insider"},{"id":6434339,"accession":"0001567619-22-015354","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001567619-22-015354","line_url":"/filing/0001567619-22-015354#line-2","is_derivative":false,"issuer_cik":"0001787306","issuer_name":"Arcutis Biotherapeutics, Inc.","issuer_ticker":"ARQT","issuer_name_source":null,"issuer_url":"/issuer/0001787306","owner_cik":"0001801061","owner_name":"Watanabe Todd Franklin","owner_display_name":"Watanabe Todd Franklin","owner_url":"/insider/0001801061","role":"Director, Officer (President and CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President and CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2500.0,"shares_display":"2,500","price_per_share":24.7432,"price_display":"24.74","price_state":"stated","total_value":61858.0,"total_display":"61,858.00","total_whole":"61,858","shares_owned_after":651871.0,"shares_owned_after_display":"651,871","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-08-05","filed_date":"2022-08-09","scope":"insider"},{"id":6979632,"accession":"0001567619-22-013924","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001567619-22-013924","line_url":"/filing/0001567619-22-013924","is_derivative":false,"issuer_cik":"0001787306","issuer_name":"Arcutis Biotherapeutics, Inc.","issuer_ticker":"ARQT","issuer_name_source":null,"issuer_url":"/issuer/0001787306","owner_cik":"0001801061","owner_name":"Watanabe Todd Franklin","owner_display_name":"Watanabe Todd Franklin","owner_url":"/insider/0001801061","role":"Director, Officer (President and CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President and CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":13500.0,"shares_display":"13,500","price_per_share":25.368355555555556,"price_display":"25.37","price_state":"stated","total_value":342472.8,"total_display":"342,472.80","total_whole":"342,473","shares_owned_after":651871.0,"shares_owned_after_display":"651,871","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-07-08","filed_date":"2022-07-12","scope":"insider","n_lines":3}],"collapsed":true,"next_cursor":"2022-07-08|6979626","ledger_fault":false,"count":{"value":82,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":3,"open_market":true},{"code":"S","label":"Open-market sale","n":79,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":82},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001787306","name":"Arcutis Biotherapeutics, Inc.","url":"/issuer/0001787306","role":"Director, Officer","n_filings":60,"first_seen":"2020-10-01","last_seen":"2026-08-05"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001801061","retrieved_at":"2026-08-24T12:13:30+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-21","last_ingest":"2026-08-22T05:23:40.159918+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}